Burkitt 淋巴瘤临床分析
王健红;高广勋;陈协群;梁蓉;郝彩霞;张娜;贾卫静;董宝侠;顾宏涛;杨岚;白庆咸;张涛
【期刊名称】《现代肿瘤医学》 【年(卷),期】2016(024)023
【摘要】Objective:To analyze the pathology,clinical features of 34 cases of Burkitt lymphoma(BL),confirmed in our center from 2007 to 2013,and the relationship between the treatment and curative effect in 12 cases.Methods:To retrospectively analyze the pathological data of 34 cases of BL diagnosed in our center 2007 -2013 (accounting for 1.43% of the total number of lymphoma in our hospital,accounting for 2.03% of B cell lymphoma)and the clinical data of 12 patients treated in our center.Chemotherapy
[hyperCVAD(A
+B)±R(rituximab)]±autologous
hemato-poietic stem cell transplantation,observe the short -term remission rate[comoplete remission (CR)and partial remis-sion (PR)]and the long -term efficacy including 1 year and 2 years overall survival rate (OS),progression free sur-vival (PFS).Results:Male∶Female =10∶7 of 34 diagnosed patients,the median age was 23.5 years (3 ~74 years), 0 ~14 29.4%(10 /34),15 ~22 23.5%(8 /34),more than 22 47.1%(16 /34).It involves in various organs of the body (mainly in lymph nodes,brain and nasopharynx);Ki -67 index were greater than 95%.Among them,12 cases treated in our center,1 case (8.4%)in phase II,4 cases(33.3%)in stage III,seven cases (58.3%)in stage IV. Receiving treatment in 12 patients,1
case with bone marrow infiltration,after 1 course treatment of the VDCP chemo-therapy,disease progression,death.11 cases (91.7%)were take 3 course of the treatment of hyperCVAD (A +B) chemotherapy,2 cases partial remission (PR),9 cases complete remission (CR),the complete remission rate was 82%.In 9 cases of CR patients,1 case treated with CHOPE regimen chemotherapy,recurrence within 1 year,5 cases take hyperCVAD (A +B)to consolidate the 6 course of chemotherapy,1 case of recurrence after 1 year,the 2 year o-verall survival rate (OS)and progression free survival (PFS)were 100% and 80%.3 cases were taked hyperCVAD (A +B)+R regimen to consolidate the 6 course of chemotherapy,followed up for 2 years without recurrence,OS and PFS was 100% in 2 years,PFS was high compared with no R supplying.3 patients were taked the treatment of autolo-gous hematopoietic stem cell transplantation after 1 year of the consolidation and maintenance treatment,followed
up
for
2
years
without
recurrence,stable
condition,OS and PFS were 100%.Among the patients(8 /11)with no recur-rence and stable disease during 2 year follow -up,less than 15 years of age accounted for 50%(4 /8),15 ~22 years old accounted for 37.5%(3 /8),more than 22 years old accounted for 12.5%(1 /8).Conclusion:Burkitt's lymphoma mainly occurs in children and adolescents,male is more than female,and it involves in various organs of the body.The diagnosis of clinical stage is often higher,chemotherapy
with high strength,high frequency and regular,can improve the prognosis and raise the complete remission rate and total survival rate,especially to children and adolescents. Combined the consolidation of rituximab with autologous stem cell transplantation therapy can improve the rate of OS and PFS.%目的:分析我中心2007年至2013年确诊的34例 Burkitt 淋巴瘤(BL)的病理、临床特征及12例临床特点和预后关系。方法:回顾分析2007年-2013年我中心确诊的34例 BL(占淋巴瘤总数1.43%,B 细胞淋巴瘤2.03%)的病理资料及12例接受治疗的患者临床资料,治疗方法为[hyperCVAD(A +B)±R(利妥昔单抗)]±自体造血干细胞移植(allo -HSCT),观察短期疗效[完全缓解(CR)和部分缓解(PR)]和长期疗效[包括1年和2年总生存率(OS)及无进展生存率(PFS)],分析预后影响因素。结果:34例患者中男∶女=10∶7,中位年龄23.5岁(3~74岁),0~14岁29.4%(10/34),15~22岁23.5%(8/34),大于22岁47.1%(16/34)。全身各脏器均可发病,主要以浅表淋巴结、脑部及鼻咽部为主。Ki -67指数均大于95%以上;c -myc 阳性77%(10/13)。其中12例在我中心接受治疗,Ⅱ期1例(8.4%),Ⅲ-Ⅳ期11例(91.7%)。诱导治疗:11例(91.7%)采用 hyperCVAD(A +B)方案化疗,3疗程后2例达 PR,9例(82%)达 CR。9例达 CR 的患者中有1例采用 CHOPE 方案巩固化疗,1年内复发;5例采用 hyperCVAD(A +B)巩固化疗6疗程,1例1年后复发,2年 OS 及 PFS 分别为100%、80%。3例采用 hyperCVAD(A +B)+利妥昔单抗(R)方案巩固化疗6疗程,2年OS 及 PFS 均为100%,PFS 较未用 R 组高。3例在巩固、维持治疗后序贯 allo -
HSCT,随访至2年无复发,病情稳定,OS 及 PFS 均为100%。随访2年无复发8例,年龄小于15岁占50%(4/8),15~22岁占37.5%(3/8),大于22岁占12.5%(1/8)。结论:BL 主要发生在儿童和青少年,男性高于女性,可累及全身各个器官,诊断时临床分期常较高,需要高强度、高频率、足疗程、规律化疗,尤其是儿童及青少年患者。利妥昔单抗和大剂量化疗药物协同使用,序贯自体造血干细胞移植巩固治疗能提高 OS 率与 PFS,但仍需要临床大样本研究。
【总页数】4页(3796-3799)
【关键词】Burkitt 淋巴瘤;hyperCVAD 方案;增殖指数
【作者】王健红;高广勋;陈协群;梁蓉;郝彩霞;张娜;贾卫静;董宝侠;顾宏涛;杨岚;白庆咸;张涛
【作者单位】第四军医大学西京医院血液内科,陕西 西安 710032;第四军医大学西京医院血液内科,陕西 西安 710032;第四军医大学西京医院血液内科,陕西 西安 710032;第四军医大学西京医院血液内科,陕西 西安 710032;第四军医大学西京医院血液内科,陕西 西安 710032;第四军医大学西京医院血液内科,陕西 西安 710032;第四军医大学西京医院血液内科,陕西 西安 710032;第四军医大学西京医院血液内科,陕西 西安 710032;第四军医大学西京医院血液内科,陕西 西安 710032;第四军医大学西京医院血液内科,陕西 西安 710032;第四军医大学西京医院血液内科,陕西 西安 710032;第四军医大学西京医院血液内科,陕西 西安 710032 【正文语种】中文 【中图分类】R733.4
【文献来源】
https://www.zhangqiaokeyan.com/academic-journal-cn_journal-modern-oncology_thesis/0201236382719.html 【相关文献】
1.具有弥漫性大B细胞淋巴瘤和经典型霍奇金淋巴瘤中间特点的灰区淋巴瘤临床病理特征 [J], 王磊; 王维格; 李小秋; 郭晔; 朱雄增
2.介于弥漫大B细胞淋巴瘤和伯基特淋巴瘤之间的未分类的B细胞淋巴瘤的临床病理诊断进展 [J], 黄慧; 杨文萍
3.青少年和成人急性T淋巴细胞白血病/淋巴瘤126例临床分析及急性早期前体T淋巴细胞白血病/淋巴瘤分型预后意义的初步探讨 [J], 廖红艳; 孙卓怡; 王彦兮; 金咏梅; 朱焕玲; 蒋能刚
4.初治淋巴瘤患者的临床治疗启示——2010 ASCO年会淋巴瘤临床治疗进展解读 [J], 朱军
5.肝脏原发黏膜相关淋巴组织结外边缘区淋巴瘤及肝脏假性淋巴瘤的临床病理特征 [J], 刘冲; 李霄; 李海; 贡其星; 李扬; 王震; 张智弘
以上内容为文献基本信息,获取文献全文请下载
Burkitt 淋巴瘤临床分析
![](/skin/haowen/images/icon_star.png)
![](/skin/haowen/images/icon_star.png)
![](/skin/haowen/images/icon_star.png)
![](/skin/haowen/images/icon_star.png)